The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir

Infection, Genetics and Evolution

Volumn 9, Issue 4, 2009, Pages 683-688

  Theys, Kristof ^a   Vercauteren, Jurgen ^a   Abecasis, Ana B ^a,b   Libin, Pieter ^a   Deforche, Koen ^a   Vandamme, Anne Mieke ^a   Camacho, Ricardo ^b,c  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b Centro Hospitalar de Lisboa Ocidental   (Portugal)

^c INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

Author keywords

Antiviral resistance; Guidelines; HIV; Incidence; K65R; Tenofovir

Indexed keywords

ABACAVIR; ARGININE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LYSINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ARTICLE; BAYESIAN LEARNING; CONTROLLED STUDY; GENE FREQUENCY; GENETIC CORRELATION; GENETIC SELECTION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NETWORK LEARNING; PORTUGAL; PREVALENCE; PRIORITY JOURNAL; TREATMENT FAILURE;

ADENINE; ANTI-HIV AGENTS; BAYES THEOREM; DATA INTERPRETATION, STATISTICAL; DATABASES, NUCLEIC ACID; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTATION; PHOSPHONIC ACIDS; PORTUGAL; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 68649109112     PISSN: 15671348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.meegid.2008.10.013     Document Type: Article

References (23)

1. Camacho, R., Theys, K., Abecasis, A., Deforche, K., Carvalho, A.P., Cabanas, J., Gomes, P., Vandamme, A.M., 2006. Rise and fall of the RT K65R incidence in the Portuguese resistance database. Abstracts of the XV International Drug Resistance Workshop, June 13-17, 2006, Sitges, Spain.
2. Deforche K., Camacho R., Grossman Z., Silander T., Soares M.A., Moreau Y., Shafer R.W., Van Laethem K., Carvalho A.P., Wynhoven B., Cane P., Snoeck J., Clarke J., Sirivichayakul S., Ariyoshi K., Holguin A., Rudich H., Rodrigues R., Bouzas M.B., Cahn P., Brigido L.F., Soriano V., Sugiura W., Phanuphak P., Morris L., Weber J., Pillay D., Tanuri A., Harrigan P.R., Shapiro J.M., Katzenstein D.A., Kantor R., and Vandamme A.M. Bayesian Network analysis of resistance pathways against protease inhibitors. Infect. Genet. Evol. 7 (2006) 382-390
3. Deforche K., Silander K., Camacho R., Grossman Z., Soares M.A., Van Laethem K., Kantor R., Moreau Y., Vandamme A.M., and nonB Workgroup. Analysis of HIV-1 pol sequences using Bayesian Networks: implications for drug resistance. Bioinformatics 22 (2006) 2975-2979
4. Deforche K., Camacho R.J., Grossman Z., Soares M.A., Van Laethem K., Katzenstein D.A., Harrigan P.R., Kantor R., Vandamme A.M., and non-B Workgroup. Bayesian Network analyses of resistance pathways against efavirenz and nevirapine. AIDS 22 (2008) 2107-2115
5. Gallant J.E., Rodriguez A.E., Weinberg W.G., Young B., Berger D.S., Lim M.L., Liao Q., Ross L., Johnson J., and Shaefer M.S. ESS300009 Study. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J. Infect. Dis. 192 (2005) 1921-1930
6. Gallant J.E., DeJesus E., Arribas J.R., Pozniak A.L., Gazzard B., Campo R.E., Lu B., McColl D., Chuck S., Enejosa J., Toole J.J., and Cheng A.K. Tenofovir DF, emtricitabine and efavirenz vs zidovudine. Lamivudine and efavirenz for HIV. Study 934 Group. N. Engl. J. Med. 354 (2006) 251-260
7. Garcia-Lerma J.G., MacInnes H., Bennett D., Reid P., Nidtha S., Weinstock H., Kaplan J.E., and Heneine W. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J. Virol. 77 (2003) 5685-5693
8. Kagan R.M., Merigan T.C., Winters M.A., and Heseltine P.N. Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization. Antivir. Ther. 9 (2004) 827-828
9. León A., Mallolas J., Martinez E., De Lazzari E., Pumarola T., Larrousse M., Milincovic A., Lonca M., Blanco J.L., Laguno M., Biglia A., and Gatell J.M. High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir. AIDS 14 (2005) 1695-1697
10. Negredo E., Molto J., Burger D., Viciana P., Ribera E., Paredes R., Juan M., Ruiz L., Puig J., Pruvost A., Grassi J., Masmitja E., and Clotet B. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 18 (2004) 459-463
11. MacArthur R.D., Crane L.R., Alvarez D., Fairfax M., Richmond D., and Curtis G. Factors associated with selection of the K65R mutation: a retrospective chart review. Antivir. Ther. 8 Suppl. 1 (2003) 237
12. Maitland D., Moyle G., Hand J., Mandalia S., Boffito M., Nelson M., and Gazzard B. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS 19 (2005) 1183-1188
13. Miller M.D. K65R TAMS and tenofovir. AIDS Rev. 6 (2004) 22-33
14. Roge B.T., Katzenstein T.L., Obel N., Nielsen H., Kirk O., Pedersen C., Mathiesen L., Lundgren J., and Gerstoft J. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir. Ther. 8 (2003) 173-182
15. Ruane P.J., and Luber A.D. K65R-associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/nucleotide reverse transcriptase inhibitor regimens. MedGenMed 6 (2004) 31
16. Torti C., Quiros-Roldon E., Regazzi M., Ladisa N., Micheli V., Orani A., Patroni A., Caputo S.L., Tirelli V., Di Giambenedetto S., Cologni G., Costarelli S., Garguilo F., Manca N., and Carosi G. Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy. RADAR Study Group of MASTER cohort. Antivir. Ther. 10 (2005) 505-513
17. Trotta M.P., Bonfigli S., Ceccherini-Silberstein F., Bellagamba R., D'Arrigo R., Soldani F., Zaccarelli M., Concetta Bellocchi M., Lorenzini P., Marconi P., Boumis E., Forbici F., Comandini U.V., Tozzi V., Narciso P., Federico Perno C., and Antinori A. Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir. J. Med. Virol. 78 (2006) 535-541
18. Valer L., Martin-Carbonero L., deMendoza C., Corral A., and Soriano V. Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations. AIDS 18 (2004) 2094-2096
19. von Wyl V., Yerly S., Boni J., Burgisser P., Klimkait T., Battegay M., Bernasconi E., Cavassini M., Furrer H., Hirschel B., Vernazza P., Rickenbach M., Ledergerber B., and Gunthard H.F. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. The Swiss HIV Cohort Study. Clin. Infect. Dis. 46 (2008) 1299-1309
20. Wainberg M.A., Brenner B.G., and Turner D. Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 41 (2005) 92-99
21. Winston A., Pozniak A., Mandalia S., Gazzard B., Pillay D., and Nelson M. Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase. AIDS 18 (2004) 949-957
22. Winters M.A., Shafer R.W., Jellinger R.A., Mamtora G., Gingeras T., and Merigan T.C. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob. Agents Chemother. 41 (1997) 757-762
23. Wirden M., Marcelin A.G., Simon A., Kirstetter M., Tubiana R., Valantin M.A., Paris L., Bonmarchand M., Conan F., Kalkias L., Katlama C., and Calvez V. Resistance mutations before and after tenofovir regimen in HIV-1 infected patients. J. Med. Virol. 76 (2005) 297-301